RPSA as a Potential Prognostic Biomarker of Pancreatic Cancer

NCT04575363 | Recruiting

• 1 other identifier: PA20113
• Study Type: interventional
• Target: 90
• Locations: 1 country
• Sites: 1

Brief Summary

PDAC (Pancreatic ductal adenocarcinoma) represents 90% of pancreatic tumors. The prognosis of PDAC remains poor at this time. Its management is based on surgery for early stages, associated with neoadjuvant and adjuvant chemotherapy. However, around 80% of patients will relapse after surgery. There is a lack of efficient biological biomarkers of PDAC, especially for prognosis. To date, CA19-9 is commonly used despite its lack of sensitivity and specificity. Ribosomal protein SA (RPSA) is a transmembrane receptor localized at the cell surface but also in the cytosolic and nuclear regions. RPSA interacts with many proteins in the extracellular matrix (ECM), including laminin-1 and elastin. RPSA in involved in different cellular functions such as cell adhesion, migration, proliferation and differentiation. The expression of RPSA is increased in many cancers including breast, lung, prostate, pancreatic, etc. It could represent a molecular biomarker of tumor invasion and metastatic abilities. Moreover, the concentration of RPSA could be measured in the serum of patients with PDAC. Recent data suggest that a modification of the RPSA concentration could be a prognostic biomarker of PDAC.

Conditions

Pancreatic Ductal Adenocarcinoma (PDAC)

Keywords

Pancreatic ductal adenocarcinoma; Ribosomal protein SA (RPSA); prognosis biomarker

Outcome Measures

Primary Outcomes (1)

• RPSA serum concentration

  The RPSA serum concentration is assessed with commercially available RPSA ELISA assay (MyBioSource - MBS9137288).

  Day 0

Study Arms (1)

pancreatic adenocarcinoma patient

EXPERIMENTAL

patient with pancreatic ductal adenocarcinoma

Other: Blood sample

Interventions

Blood sample OTHER

Blood sample

pancreatic adenocarcinoma patient

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients treated at the Reims University Hospital for a resectable or potentially resectable pancreatic tumor, with or without neoadjuvant chemotherapy
• Adults (aged more than 18 years old)
• Patients who have signed the informed consent form

You may not qualify if:

• Patients with a prior history of cancer (excluding basal cell carcinoma or in situ cervical cancer that received conventional cancer treatment).
• Minors
• Patients for whom PDAC is not the retained diagnosis

Sponsors & Collaborators

• CHU de Reims: lead

Study Sites (1)

Damien JOLLY

Reims, France

RECRUITING

MeSH Terms

Interventions

Blood Specimen Collection

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Central Study Contacts

Jean-Baptiste OUDART

CONTACT

03 10 73 62 87; joudart@chu-reims.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 29, 2020
• First Posted: October 5, 2020
• Study Start: October 18, 2021
• Primary Completion (Estimated): October 18, 2026
• Study Completion (Estimated): October 18, 2027
• Last Updated: November 9, 2023

Record last verified: 2023-11

Locations

FR (1)